In addition, Dickerson and colleagues [130] acknowledged that the absence of an association between IgM levels and cognitive impairment in patients with schizophrenia—and the weaker association observed in the bipolar group compared to nonpsychiatric controls—could, at least in part, be explained by the anti-Toxoplasma effects of antipsychotic medications used in the treatment of both schizophrenia and bipolar disorder. The gene discussed is CD40LG; the disease is schizophrenia.